Rapid determination of colistin resistance in clinical strains of acinetobacter baumannii by use of the micromax assay

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3675-3682

  Tamayo, Maria ^a,b   Santiso, Rebeca ^a,b   Otero, Fátima ^a,b   Bou, Germán ^a   Lepe, José Antonio ^c   McConnell, Michael J ^c   Cisneros, José Miguel ^c   Gosálvez, Jaime ^d   Fernández, José Luis ^a,b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b Centro Oncologico de Galicia   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN;

ACCURACY; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOASSAY; CELL DAMAGE; CELLULAR SECRETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; FLUORESCENCE MICROSCOPY; INCUBATION TIME; LYSIS; MICROMAX ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOID; PRIORITY JOURNAL; RAPID TEST; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIOLYSIS; CELL WALL; CHROMOSOMES, BACTERIAL; COLISTIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84886581511     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01787-13     Document Type: Article

References (35)

1. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. 1998. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J. Clin. Microbiol. 36:1938-1941.
2. Peleg AY, Hooper DC. 2010. Hospital-acquired infections due to Gramnegative bacteria. N. Engl. J. Med. 362:1804-1813.
3. Gootz TD, Marra A. 2008. Acinetobacter baumannii: an emerging multidrug- resistant threat. Expert Rev. Anti Infect. Ther. 6:309-325.
4. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
5. Taccone FS, Rodriguez-Villalobos H, De Backer D, De Moor V, Deviere J, Vincent JL, Jacobs F. 2006. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur. J. Clin. Microbiol. Infect. Dis. 25:257-260.
6. Falagas ME, Bliziotis IA. 2007. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era? Int. J. Antimicrob. Agents 29:630-636.
7. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrugresistant Gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341.
8. Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P. 2006. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J. Antimicrob. Chemother. 57:1251-1254.
9. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21:449-465.
10. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
11. Nation RL, Li J. 2009. Colistin in the 21st Century. Curr. Opin. Infect. Dis. 22:535-543.
12. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J. Antimicrob. Chemother. 60:1206-1215.
13. Hancock REW. 1997. Peptide antibiotics. Lancet 349:418-422.
14. Evans ME, Feola DJ, Rapp RP. 1999. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann. Pharmacother. 33:960-977.
15. Hermsen ED, Sullivan CJ, Rotschafer JC. 2003. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect. Dis. Clin. North. Am. 17:545-562.
16. Abraham N, Kwon DH. 2009. A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa. FEMS Microbiol. Lett. 298:249-254.
17. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634.
18. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoethanolamine modification of lipid A in colistin resistant variants of Acinetobacter baumannii mediated by the pmrAB twocomponent regulatory system. Antimicrob. Agents Chemother. 55: 3370-3379.
19. Lee H, Hsu FF, Turk J, Groisman EA. 2004. The PmrA-regulated pmrC gene mediates phosphoethanolamine modification of lipid A and polymyxin resistance in Salmonella enterica. J. Bacteriol. 186: 4124-4133.
20. Nummila K, Kilpeläinen I, Zähringer U, Vaara M, Helander IM. 1995. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol. Microbiol. 16:271-278.
21. Trent MS, Ribeiro AA, Lin S, Cotter RJ, Raetz CR. 2001. An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino- 4-deoxy-L-arabinose to lipid A: induction on polymyxin-resistant mutants and role of a novel lipid-linked donor. J. Biol. Chem. 276:43122-43131.
22. Ko KS, Suh JY, Kwon KT, Jung SI, Park KH, Kang CI, Chung DR, Peck KR, Song JH. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60:1163-1167.
23. Park YK, Jung SI, Park KH, Cheong HS, Peck KR, Song JH, Ko KS. 2009. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn. Microbiol. Infect. Dis. 64:43-51.
24. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40.
25. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. 2002. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122:262-268.
26. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. 2008. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibioticresistant Gram-negative bacteria. Chest 134:281-287.
27. Bou G, Otero FM, Santiso R, Tamayo M, Fernández MC, Tomás M, Gosálvez J, Fernández JL. 2012. Fast assessment of resistance to carbapenems and ciprofloxacin of clinical strains of Acinetobacter baumannii. J. Clin. Microbiol. 50:3609-3613.
28. Santiso R, Tamayo M, Gosálvez J, Bou G, Fernández MC, Fernández JL. 2011. A rapid in situ procedure for determination of bacterial susceptibility or resistance to antibiotics that inhibit peptidoglycan biosynthesis. BMC Microbiol. 11:191. doi:10.1186/1471-2180-11-19.
29. Fernández JL, Cartelle M, Muriel L, Santiso R, Tamayo M, Goyanes V, Gosálvez J, Bou G. 2008. DNA fragmentation in microorganisms assessed in situ. Appl. Environ. Microbiol. 74:5925-5933.
30. Santiso R, Tamayo M, Fernández JL, Fernández MC, Molina F, Villanueva R, Gosálvez J, Bou G. 2009. Rapid and simple determination of ciprofloxacin resistance in clinical strains of Escherichia coli. J. Clin. Microbiol. 47:2593-2595.
31. Tamayo M, Santiso R, Gosálvez J, Bou G, Fernández JL. 2009. Rapid assessment of ciprofloxacin effect on chromosomalDNAfrom Escherichia coli with an in situ DNA fragmentation assay. BMC Microbiol. 9:69. doi: 10.1186/1471-2180-9-69.
32. Fernández-Reyes M, Rodríguez-Falcón M, Chiva C, Pachón J, Andreu D, Rivas L. 2009. The cost of resistance to colistin in Acinetobacter baumannii: a proteomic perspective. Proteomics 9:1632-1645.
33. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide. Antimicrob. Agents Chemother. 54:4971-4977.
34. Soon RL, Nation RL, Cockram S, Moffatt JH, Harper M, Adler B, Boyce JD, Larson I, Li J. 2011. Different surface charge of colistin-susceptible and -resistant Acinetobacter baumannii cells measured with zeta potential as a function of growth phase and colistin treatment. J. Antimicrob. Chemother. 66:126-133.
35. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810